Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 37

1.

MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine.

Visani G, Loscocco F, Ruzzo A, Galimberti S, Graziano F, Voso MT, Giacomini E, Finelli C, Ciabatti E, Fabiani E, Barulli S, Volpe A, Magro D, Piccaluga P, Fuligni F, Vignetti M, Fazi P, Piciocchi A, Gabucci E, Rocchi M, Magnani M, Isidori A.

Pharmacogenomics J. 2017 Dec 5. doi: 10.1038/tpj.2017.48. [Epub ahead of print]

PMID:
29205204
2.

Comprehensive Analysis of Hypermutation in Human Cancer.

Campbell BB, Light N, Fabrizio D, Zatzman M, Fuligni F, de Borja R, Davidson S, Edwards M, Elvin JA, Hodel KP, Zahurancik WJ, Suo Z, Lipman T, Wimmer K, Kratz CP, Bowers DC, Laetsch TW, Dunn GP, Johanns TM, Grimmer MR, Smirnov IV, Larouche V, Samuel D, Bronsema A, Osborn M, Stearns D, Raman P, Cole KA, Storm PB, Yalon M, Opocher E, Mason G, Thomas GA, Sabel M, George B, Ziegler DS, Lindhorst S, Issai VM, Constantini S, Toledano H, Elhasid R, Farah R, Dvir R, Dirks P, Huang A, Galati MA, Chung J, Ramaswamy V, Irwin MS, Aronson M, Durno C, Taylor MD, Rechavi G, Maris JM, Bouffet E, Hawkins C, Costello JF, Meyn MS, Pursell ZF, Malkin D, Tabori U, Shlien A.

Cell. 2017 Nov 16;171(5):1042-1056.e10. doi: 10.1016/j.cell.2017.09.048. Epub 2017 Oct 19.

PMID:
29056344
3.

Low-dose lenalidomide plus cytarabine in very elderly, unfit acute myeloid leukemia patients: Final result of a phase II study.

Visani G, Ferrara F, Di Raimondo F, Loscocco F, Fuligni F, Paolini S, Zammit V, Spina E, Rocchi M, Visani A, Piccaluga PP, Isidori A.

Leuk Res. 2017 Nov;62:77-83. doi: 10.1016/j.leukres.2017.09.019. Epub 2017 Sep 25.

4.

Prevention of large-scale implementation of unnecessary and expensive predictive tests in Hodgkin's lymphoma - Authors' reply.

Agostinelli C, Gallamin A, Fuligni F, Stracqualursi L, Agati P, Zinzani PL, Pileri SA.

Lancet Haematol. 2017 Feb;4(2):e64-e66. doi: 10.1016/S2352-3026(17)30002-9. No abstract available.

PMID:
28159191
5.

Distinctive Histogenesis and Immunological Microenvironment Based on Transcriptional Profiles of Follicular Dendritic Cell Sarcomas.

Laginestra MA, Tripodo C, Agostinelli C, Motta G, Hartmann S, Döring C, Rossi M, Melle F, Sapienza MR, Tabanelli V, Pileri A, Fuligni F, Gazzola A, Mannu C, Sagramoso CA, Lonardi S, Lorenzi L, Bacci F, Sabattini E, Borges A, Simonitsch-Klupp I, Cabecadas J, Campo E, Rosai J, Hansmann ML, Facchetti F, Pileri SA.

Mol Cancer Res. 2017 May;15(5):541-552. doi: 10.1158/1541-7786.MCR-16-0301. Epub 2017 Jan 27.

PMID:
28130401
6.

Spleen histology in children with sickle cell disease and hereditary spherocytosis: hints on the disease pathophysiology.

Pizzi M, Fuligni F, Santoro L, Sabattini E, Ichino M, De Vito R, Zucchetta P, Colombatti R, Sainati L, Gamba P, Alaggio R.

Hum Pathol. 2017 Feb;60:95-103. doi: 10.1016/j.humpath.2016.09.028. Epub 2016 Oct 19.

PMID:
27771375
7.

The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study.

Agostinelli C, Gallamini A, Stracqualursi L, Agati P, Tripodo C, Fuligni F, Sista MT, Fanti S, Biggi A, Vitolo U, Rigacci L, Merli F, Patti C, Romano A, Levis A, Trentin L, Stelitano C, Borra A, Piccaluga PP, Hamilton-Dutoit S, Kamper P, Zaucha JM, Małkowski B, Kulikowski W, Tajer J, Subocz E, Rybka J, Steidl C, Broccoli A, Argnani L, Gascoyne RD, d'Amore F, Zinzani PL, Pileri SA.

Lancet Haematol. 2016 Oct;3(10):e467-e479. doi: 10.1016/S2352-3026(16)30108-9.

PMID:
27692305
8.

Direct Transcriptional Consequences of Somatic Mutation in Breast Cancer.

Shlien A, Raine K, Fuligni F, Arnold R, Nik-Zainal S, Dronov S, Mamanova L, Rosic A, Ju YS, Cooke SL, Ramakrishna M, Papaemmanuil E, Davies HR, Tarpey PS, Van Loo P, Wedge DC, Jones DR, Martin S, Marshall J, Anderson E, Hardy C; ICGC Breast Cancer Working Group, Oslo Breast Cancer Research Consortium, Barbashina V, Aparicio SA, Sauer T, Garred Ø, Vincent-Salomon A, Mariani O, Boyault S, Fatima A, Langerød A, Borg Å, Thomas G, Richardson AL, Børresen-Dale AL, Polyak K, Stratton MR, Campbell PJ.

Cell Rep. 2016 Aug 16;16(7):2032-46. doi: 10.1016/j.celrep.2016.07.028. Epub 2016 Aug 4.

9.

miRNA expression profiling divides follicular dendritic cell sarcomas into two groups, related to fibroblasts and myopericytomas or Castleman's disease.

Hartmann S, Döring C, Agostinelli C, Portscher-Kim SJ, Lonardi S, Lorenzi L, Fuligni F, Martinez D, Mehta J, Borges A, Hackstein H, Kippenberger S, Piccaluga PP, Simonitsch-Klupp I, Cabeçadas J, Campo E, Facchetti F, Pileri SA, Hansmann ML.

Eur J Cancer. 2016 Sep;64:159-66. doi: 10.1016/j.ejca.2016.06.004. Epub 2016 Jul 15.

PMID:
27423414
10.

Distinct Viral and Mutational Spectrum of Endemic Burkitt Lymphoma.

Abate F, Ambrosio MR, Mundo L, Laginestra MA, Fuligni F, Rossi M, Zairis S, Gazaneo S, De Falco G, Lazzi S, Bellan C, Rocca BJ, Amato T, Marasco E, Etebari M, Ogwang M, Calbi V, Ndede I, Patel K, Chumba D, Piccaluga PP, Pileri S, Leoncini L, Rabadan R.

PLoS Pathog. 2015 Oct 15;11(10):e1005158. doi: 10.1371/journal.ppat.1005158. eCollection 2015 Oct.

11.

A case of lineage switch from B-cell acute lymphoblastic leukaemia to acute myeloid leukaemia. Role of subclonal/clonal gene mutations.

Della Starza I, Ceglie G, Nunes V, Gianfelici V, Marinelli M, Fuligni F, De Novi LA, De Propris MS, Vitale A, Chiaretti S, Guarini A, Foà R.

Br J Haematol. 2016 Aug;174(4):648-51. doi: 10.1111/bjh.13800. Epub 2015 Oct 12. No abstract available.

PMID:
26456857
12.

Burkitt lymphoma beyond MYC translocation: N-MYC and DNA methyltransferases dysregulation.

De Falco G, Ambrosio MR, Fuligni F, Onnis A, Bellan C, Rocca BJ, Navari M, Etebari M, Mundo L, Gazaneo S, Facchetti F, Pileri SA, Leoncini L, Piccaluga PP.

BMC Cancer. 2015 Oct 9;15:668. doi: 10.1186/s12885-015-1661-7.

13.

Virus-encoded microRNA contributes to the molecular profile of EBV-positive Burkitt lymphomas.

Piccaluga PP, Navari M, De Falco G, Ambrosio MR, Lazzi S, Fuligni F, Bellan C, Rossi M, Sapienza MR, Laginestra MA, Etebari M, Rogena EA, Tumwine L, Tripodo C, Gibellini D, Consiglio J, Croce CM, Pileri SA, Leoncini L.

Oncotarget. 2016 Jan 5;7(1):224-40. doi: 10.18632/oncotarget.4399.

14.

The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T-cell lymphoma.

Marchi E, Zullo KM, Amengual JE, Kalac M, Bongero D, McIntosh CM, Fogli LK, Rossi M, Zinzani PL, Pileri SA, Piccaluga PP, Fuligni F, Scotto L, O'Connor OA.

Br J Haematol. 2015 Jul 20. doi: 10.1111/bjh.13566. [Epub ahead of print]

PMID:
26194163
15.

IFI16 Expression Is Related to Selected Transcription Factors during B-Cell Differentiation.

Piccaluga PP, Agostinelli C, Fuligni F, Righi S, Tripodo C, Re MC, Clò A, Miserocchi A, Morini S, Gariglio M, Ferri GG, Rinaldi-Ceroni A, Piccin O, De Andrea M, Pileri SA, Landolfo S, Gibellini D.

J Immunol Res. 2015;2015:747645. doi: 10.1155/2015/747645. Epub 2015 Jun 22.

16.

SOCS2 Controls Proliferation and Stemness of Hematopoietic Cells under Stress Conditions and Its Deregulation Marks Unfavorable Acute Leukemias.

Vitali C, Bassani C, Chiodoni C, Fellini E, Guarnotta C, Miotti S, Sangaletti S, Fuligni F, De Cecco L, Piccaluga PP, Colombo MP, Tripodo C.

Cancer Res. 2015 Jun 1;75(11):2387-99. doi: 10.1158/0008-5472.CAN-14-3625. Epub 2015 Apr 9.

17.

Protein kinase CK2 is widely expressed in follicular, Burkitt and diffuse large B-cell lymphomas and propels malignant B-cell growth.

Pizzi M, Piazza F, Agostinelli C, Fuligni F, Benvenuti P, Mandato E, Casellato A, Rugge M, Semenzato G, Pileri SA.

Oncotarget. 2015 Mar 30;6(9):6544-52.

18.

Molecular signature of Epstein Barr virus-positive Burkitt lymphoma and post-transplant lymphoproliferative disorder suggest different roles for Epstein Barr virus.

Navari M, Fuligni F, Laginestra MA, Etebari M, Ambrosio MR, Sapienza MR, Rossi M, De Falco G, Gibellini D, Tripodo C, Pileri SA, Leoncini L, Piccaluga PP.

Front Microbiol. 2014 Dec 23;5:728. doi: 10.3389/fmicb.2014.00728. eCollection 2014.

19.

Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma.

Derenzini E, Agostinelli C, Imbrogno E, Iacobucci I, Casadei B, Brighenti E, Righi S, Fuligni F, Ghelli Luserna Di Rorà A, Ferrari A, Martinelli G, Pileri S, Zinzani PL.

Oncotarget. 2015 Mar 30;6(9):6553-69.

20.

Pathogenetic and diagnostic significance of microRNA deregulation in peripheral T-cell lymphoma not otherwise specified.

Laginestra MA, Piccaluga PP, Fuligni F, Rossi M, Agostinelli C, Righi S, Sapienza MR, Motta G, Gazzola A, Mannu C, Sabattini E, Bacci F, Tabanelli V, Sacchetti CA, Barrese TZ, Etebari M, Melle F, Clò A, Gibellini D, Tripodo C, Inghirami G, Croce CM, Pileri SA.

Blood Cancer J. 2014 Nov 7;4:259. doi: 10.1038/bcj.2014.78.

Supplemental Content

Loading ...
Support Center